Literature DB >> 36138147

Phenotype, genotype, and management of congenital fibrosis of extraocular muscles type 1 in 16 Chinese families.

Moxin Chen1,2, Rui Huang1,2, Yingjie Zhang1,2, Deyi Jasmine Zhu3, Qin Shu1,2, Pengcheng Xun4, Jing Zhang5,6, Ping Gu7,8, Lin Li9,10.   

Abstract

PURPOSE: Congenital fibrosis of extraocular muscles type 1 (CFEOM1), a classical subtype of CFEOM, is characterized by restrictive ophthalmoplegia and ptosis. It is mainly caused by aberrant neural innervation of the extraocular muscles. This study aimed to investigate the genetic characteristics and clinical manifestations of CFEOM1 in Chinese families.
METHODS: The clinical data, including ocular examinations, magnetic resonance imaging (MRI), and surgical procedures of affected individuals from 16 Chinese CFEOM1 families, were collected. The genomic DNA of 16 probands and their family members were sequenced for causative KIF21A gene mutations. Linkage analysis using microsatellite markers across KIF21A was also conducted.
RESULTS: Affected individuals were presented with bilateral non-progressive ptosis, restricted horizontal eye movement, fixed infraduction of both eyes, compensatory chin-up head position, and neuromuscular abnormalities. Three heterozygous KIF21A mutations, c.2860C > T (p.R954W) (in eight families), c.2861G > T (p.R954L) (in two families), and c.2861G > A (p.R954Q) (in two families) were identified, which implied that hotspot mutations were common in Chinese CFEOM1 families. Germline Mosaicism was likely to be the cause of affected individuals with asymptomatic parents without KIF21A mutations presented in the eight families. Two affected individuals underwent modified levator muscle complex suspension surgery and achieved a good result without any complications.
CONCLUSION: Instead of evaluating the whole CFEOM1 gene variant, hotspot mutations could be given priority for screening. The occurrence of germline mosaicism has to be taken into account in genetic counseling. Patients with CFEOM1 who have ptosis may benefit from an innovative surgical procedure called modified levator muscle complex suspension.
© 2022. The Author(s).

Entities:  

Keywords:  CFEOM1; Hotspot mutations; KIF21A; Ptosis

Year:  2022        PMID: 36138147     DOI: 10.1007/s00417-022-05830-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.535


  41 in total

1.  Heterozygous mutations of the kinesin KIF21A in congenital fibrosis of the extraocular muscles type 1 (CFEOM1).

Authors:  Koki Yamada; Caroline Andrews; Wai-Man Chan; Craig A McKeown; Adriano Magli; Teresa de Berardinis; Anat Loewenstein; Moshe Lazar; Michael O'Keefe; Robert Letson; Arnold London; Mark Ruttum; Naomichi Matsumoto; Nakamichi Saito; Lisa Morris; Monte Del Monte; Roger H Johnson; Eiichiro Uyama; Willem A Houtman; Berendina de Vries; Thomas J Carlow; Blaine L Hart; Nicolas Krawiecki; John Shoffner; Marlene C Vogel; James Katowitz; Scott M Goldstein; Alex V Levin; Emin C Sener; Banu T Ozturk; A Nurten Akarsu; Michael C Brodsky; Frank Hanisch; Robert P Cruse; Alina A Zubcov; Richard M Robb; Peter Roggenkäemper; Irene Gottlob; Lionel Kowal; Ravi Battu; Elias I Traboulsi; Piergiorgio Franceschini; Anna Newlin; Joseph L Demer; Elizabeth C Engle
Journal:  Nat Genet       Date:  2003-11-02       Impact factor: 38.330

2.  Magnetic resonance imaging evidence for widespread orbital dysinnervation in congenital fibrosis of extraocular muscles due to mutations in KIF21A.

Authors:  Joseph L Demer; Robert A Clark; Elizabeth C Engle
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-02       Impact factor: 4.799

3.  Neurological features of congenital fibrosis of the extraocular muscles type 2 with mutations in PHOX2A.

Authors:  Thomas M Bosley; Darren T Oystreck; Richard L Robertson; Abdulaziz al Awad; Khaled Abu-Amero; Elizabeth C Engle
Journal:  Brain       Date:  2006-06-30       Impact factor: 13.501

Review 4.  Congenital fibrosis of the extraocular muscles: review of recent literature.

Authors:  Jade M Price; Ranjodh S Boparai; Barry N Wasserman
Journal:  Curr Opin Ophthalmol       Date:  2019-09       Impact factor: 3.761

5.  The recurrent TUBB3 Gly98Ser substitution is the first described to inconsistently result in CFEOM3.

Authors:  Scott C Smith; Ann Haskins Olney; Angela Beavers; Joanna Spaulding; Marilu Nelson; Shelly Nielsen; Jennifer N Sanmann
Journal:  Am J Med Genet A       Date:  2020-07-24       Impact factor: 2.802

6.  Phenotypic heterogeneity may occur in congenital fibrosis of the extraocular muscles.

Authors:  A C Reck; R Manners; E Hatchwell
Journal:  Br J Ophthalmol       Date:  1998-06       Impact factor: 4.638

7.  Retinal Dysfunction in Patients with Congenital Fibrosis of the Extraocular Muscles Type 2.

Authors:  Arif O Khan; Mohammed Almutlaq; Darren T Oystreck; Elizabeth C Engle; Khaled Abu-Amero; Thomas Bosley
Journal:  Ophthalmic Genet       Date:  2014-06-18       Impact factor: 1.803

8.  A Novel De Novo KIF21A Variant in a Patient With Congenital Fibrosis of the Extraocular Muscles With a Syndromic CFEOM Phenotype.

Authors:  Luca Soliani; Carlotta Spagnoli; Grazia G Salerno; Miika Mehine; Susanna Rizzi; Daniele Frattini; Juha Koskenvuo; Carlo Fusco
Journal:  J Neuroophthalmol       Date:  2021-03-01       Impact factor: 3.042

9.  KIF21A pathogenic variants cause congenital fibrosis of extraocular muscles type 3.

Authors:  Christiane Al-Haddad; Rose-Mary Boustany; Elza Rachid; Karine Ismail; Brenda Barry; Wai-Man Chan; Elizabeth Engle
Journal:  Ophthalmic Genet       Date:  2020-11-29       Impact factor: 1.803

10.  Novel variants in TUBA1A cause congenital fibrosis of the extraocular muscles with or without malformations of cortical brain development.

Authors:  Julie A Jurgens; Brenda J Barry; Gabrielle Lemire; Wai-Man Chan; Mary C Whitman; Sherin Shaaban; Caroline D Robson; Sarah MacKinnon; Eleina M England; Hugh J McMillan; Christopher Kelly; Brandon M Pratt; Anne O'Donnell-Luria; Daniel G MacArthur; Kym M Boycott; David G Hunter; Elizabeth C Engle
Journal:  Eur J Hum Genet       Date:  2021-03-01       Impact factor: 5.351

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.